Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

• DOI: 10.1007/s10753-012-9440-y
• Publication Date: 2012-02-20T23:40:46Z
• Authors: Wenchao Hu; Qian Yu; Jie Zhang; Demin Liu
• Keywords: Blood Glucose; Male; 0303 health sciences; Pioglitazone; Body Weight; Connective Tissue Growth Factor; Intercellular Adhesion Molecule-1; Kidney; Diabetes Mellitus, Experimental; Rats; 3. Good health; Rats, Sprague-Dawley; Rosiglitazone; Transforming Growth Factor beta1; Random Allocation; 03 medical and health sciences; Adipokines; Animals; Intercellular Signaling Peptides and Proteins; Diabetic Nephropathies; Receptors, Chemokine; Thiazolidinediones; Chemokines

Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. This study aims to determine whether rosiglitazone and pioglitazone ameliorate renal function through an effect on the expression of chemerin and ChemR23 in streptozotocin-induced diabetic rats. The rats were randomized to control, diabetic, rosiglitazone-, and pioglitazone-treated groups. The expression level of chemerin and ChemR23 in the renal tissues was significantly elevated in the diabetic group compared with the control group. Rosiglitazone inhibited the overexpression of chemerin and ChemR23, while pioglitazone inhibited the overexpression of ChemR23 in the kidney of diabetic rats. In addition, chemerin expression level was positively correlated with transforming growth factor-β1, connective tissue growth factor, tumor necrosis factor-α, and intracellular cell adhesion molecule-1 expression in diabetic rats. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats.